Longlong Luo

611 total citations
49 papers, 364 citations indexed

About

Longlong Luo is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Longlong Luo has authored 49 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Immunology, 15 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Longlong Luo's work include Cancer Immunotherapy and Biomarkers (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and CAR-T cell therapy research (6 papers). Longlong Luo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and CAR-T cell therapy research (6 papers). Longlong Luo collaborates with scholars based in China, Czechia and Uganda. Longlong Luo's co-authors include Jiannan Feng, Ning Shi, Haitao Zhuo, Shaojun Chen, Caiping Ren, Chunxia Qiao, Xingjun Jiang, Bing Shen, Yujun Liu and Jing Wang and has published in prestigious journals such as Journal of Virology, Scientific Reports and Biochemical and Biophysical Research Communications.

In The Last Decade

Longlong Luo

43 papers receiving 356 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Longlong Luo China	12	119	91	84	64	54	49	364
Peter A. Bielecki United States	10	154 1.3×	91 1.0×	108 1.3×	55 0.9×	15 0.3×	15	573
Yanling Jin China	12	125 1.1×	32 0.4×	123 1.5×	216 3.4×	29 0.5×	18	541
James Wang United States	12	86 0.7×	114 1.3×	159 1.9×	11 0.2×	52 1.0×	30	510
Shuaishuai Liu China	7	96 0.8×	58 0.6×	204 2.4×	65 1.0×	11 0.2×	12	453
Xueru Song China	12	123 1.0×	161 1.8×	157 1.9×	28 0.4×	25 0.5×	22	537
Yina Wu South Korea	13	170 1.4×	46 0.5×	198 2.4×	6 0.1×	27 0.5×	18	428
Tanmay Dichwalkar United States	4	198 1.7×	258 2.8×	155 1.8×	20 0.3×	28 0.5×	6	418
Lanxiang Huang China	11	165 1.4×	164 1.8×	327 3.9×	24 0.4×	8 0.1×	13	611
Afshin Mashadi-Hossein United States	10	167 1.4×	282 3.1×	176 2.1×	10 0.2×	65 1.2×	27	620

Countries citing papers authored by Longlong Luo

Since Specialization

Citations

This map shows the geographic impact of Longlong Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Longlong Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Longlong Luo more than expected).

Fields of papers citing papers by Longlong Luo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Longlong Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Longlong Luo. The network helps show where Longlong Luo may publish in the future.

Co-authorship network of co-authors of Longlong Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Longlong Luo. A scholar is included among the top collaborators of Longlong Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Longlong Luo. Longlong Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Jie, Ning Shi, Xuechen Yang, et al.. (2025). Comparative evaluation of bispecific antibody formats targeting PD-1 and LAG-3 for dual checkpoint blockade in cancer immunotherapy. Biomedicine & Pharmacotherapy. 192. 118583–118583.

Yang, Cong, Yawen Wu, Di Jing, et al.. (2025). Molecular Epidemiology of Brucella spp. in Aborted Livestock in the Ningxia Hui Autonomous Region, China. Veterinary Sciences. 12(8). 702–702.

Yao, Ying, Juan Tian, Ran Zhang, et al.. (2025). Nanobody-based radiotracers in nuclear medicine: Advances, challenges, and future perspectives. Chinese Chemical Letters. 37(6). 111517–111517. 1 indexed citations

Long, Yu, Fei Xie, Lianqi Liu, et al.. (2025). Novel Quaternary Ammonium Salt‐Linked STING Agonist Antibody‐Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off‐Target Toxicity. Advanced Science. 12(31). e02270–e02270. 2 indexed citations

Tian, Juan, et al.. (2025). Development and Characterization of 4A7: A High-Affinity Monoclonal Antibody Targeting Claudin18.2. ImmunoTargets and Therapy. Volume 14. 189–203. 1 indexed citations

Wang, Zhihong, Hui Dong, Ning Shi, et al.. (2024). Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2. Advanced Science. 11(45). e2402975–e2402975. 3 indexed citations

Zhang, Liang, Yujun Liu, Ning Shi, et al.. (2024). Detection of TNF-α using the established ab-MPs-CLIA. Talanta. 285. 127301–127301. 3 indexed citations

Li, Shasha, Hui Liu, Weidong Liu, et al.. (2023). ESRG is critical to maintain the cell survival and self-renewal/pluripotency of hPSCs by collaborating with MCM2 to suppress p53 pathway. International Journal of Biological Sciences. 19(3). 916–935. 11 indexed citations

Zhang, Yuting, Min Zhang, Xinwei Wang, et al.. (2023). A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus. eLife. 12. 3 indexed citations

10.

Hu, Naijing, Yingjun Liu, Longlong Luo, et al.. (2023). Functional epitopes and neutralizing antibodies of vaccinia virus. Frontiers in Microbiology. 14. 1255935–1255935. 2 indexed citations

11.

Liu, Yujun, et al.. (2023). The application of Interleukin-2 family cytokines in tumor immunotherapy research. Frontiers in Immunology. 14. 1090311–1090311. 27 indexed citations

12.

Wang, Chuanjie, Zhaolin Sun, Ming Wang, et al.. (2022). Novel CRISPR/Cas9-mediated knockout of LIG4 increases efficiency of site-specific integration in Chinese hamster ovary cell line. Biotechnology Letters. 44(9). 1063–1072. 5 indexed citations

13.

Shi, Ning, Yujun Liu, Ran Zhang, et al.. (2022). PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy. Frontiers in Immunology. 13. 1047610–1047610. 22 indexed citations

14.

Li, Zhi, Hua Xu, Lei Guo, et al.. (2021). Label-free differentiation and quantification of ricin, abrin from their agglutinin biotoxins by surface plasmon resonance. Talanta. 238. 122860–122860. 18 indexed citations

15.

Sun, Ying, Min Zhang, Xinwei Wang, et al.. (2021). pH Low Insertion Peptide-Modified Programmed Cell Death-Ligand 1 Potently Suppresses T-Cell Activation Under Acidic Condition. Frontiers in Immunology. 12. 794226–794226. 4 indexed citations

16.

Wang, Zhihong, Naijing Hu, Xinying Li, et al.. (2021). Selection and Characterization of FD164, a High-Affinity Signal Regulatory Protein α Variant with Balanced Safety and Effectiveness, from a Targeted Epitope Mammalian Cell-Displayed Antibody Library. Molecular Pharmacology. 100(3). 193–202. 5 indexed citations

17.

Hu, Naijing, Chunxia Qiao, Jing Wang, et al.. (2021). Identification of a novel protective human monoclonal antibody, LXY8, that targets the key neutralizing epitopes of staphylococcal enterotoxin B. Biochemical and Biophysical Research Communications. 549. 120–127. 11 indexed citations

18.

Liu, Hui, Shasha Li, Caiping Ren, et al.. (2020). Generation of an ESRG Pr-tdTomato reporter human embryonic stem cell line, CSUe011-A, using CRISPR/Cas9 editing. Stem Cell Research. 48. 101983–101983. 4 indexed citations

19.

Duan, Yanting, Longlong Luo, Chunxia Qiao, et al.. (2019). A novel human anti‐AXL monoclonal antibody attenuates tumour cell migration. Scandinavian Journal of Immunology. 90(2). e12777–e12777. 23 indexed citations

20.

Wang, Qun, Jing Yang, Tang Kun, et al.. (2014). Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC Biotechnology. 14(1). 17–17. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact